Mubadala Investment Co PJSC
SEC CIK 1704268 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | 10% | 12.99M | $2.91M | — | 9 | 2022-10-27 | 2023-03-02 |
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Mubadala Investment Co PJSC made no open-market trades at RXRX in the last 12 months.
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-03-03 | 2023-03-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.82 | +66.8K | 12.99M | +0.5% | +$522.5K |
| I | 2023-03-02 | 2023-03-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.94 | +48.9K | 12.92M | +0.4% | +$388.0K |
| I | 2023-03-01 | 2023-02-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +815 | 12.87M | +0.0% | +$6,496 |
| I | 2023-02-28 | 2023-02-27 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.69 | +52.5K | 12.87M | +0.4% | +$403.7K |
| I | 2023-02-27 | 2023-02-24 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.64 | +109.1K | 12.82M | +0.9% | +$833.7K |
| I | 2023-02-21 | 2023-02-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.71 | +63.4K | 12.51M | +0.5% | +$488.7K |
| I | 2023-02-14 | 2023-02-13 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +32.5K | 12.40M | +0.3% | +$258.8K |
| I | 2023-02-02 | 2023-02-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +600 | 12.35M | +0.0% | +$4,782 |
| I | 2022-10-31 | 2022-10-27 | RXRX | RECURSION PHARMACEUTICALS, INC. | Mubadala Investment Co PJSC | 10% | A - Grant | $9.80 | +2.55M | 11.29M | +29% | +$25.00M |
Purchase Sale Sale after option exercise All abbreviations